Patents by Inventor Victor Harris

Victor Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7417068
    Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: August 26, 2008
    Assignee: Asterand UK Limited
    Inventors: David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark
  • Publication number: 20080119526
    Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3
    Type: Application
    Filed: December 5, 2007
    Publication date: May 22, 2008
    Applicant: PHARMAGENE LABORATORIES LIMITED
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7326732
    Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and t
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: February 5, 2008
    Assignee: Pharmagene Laboratories Limited
    Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
  • Patent number: 7211586
    Abstract: The invention is directed to physiologically active compounds of formula (I): wherein: R1 represents optionally substituted aryl, optionally substituted heteroaryl, R3NH—Ar1—L2— or R3—NH—C(?O)—NH—Ar2—L2—; R3 represents aryl or heteroaryl; Ar1 represents a saturated, partially saturated or fully unsaturated 8- to 10-membered bicyclic ring system containing at least one heteroatom selected from O, S or N; Ar2 represents aryldiyl or heteroaryldiyl; L1 represents a linkage, such as an alkylene linkage; L2 represents an alkylene chain linkage; R2 represents hydrogen, halogen, C1-4alkyl or C1-4alkoxy; and Y is carboxy or an acid bioisostere; but excluding compounds where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue; and the corresponding N-oxides and ester prodrugs thereof, and the pharmaceutically acceptable salts and solvates of such compounds, and the N-oxides and ester prodrugs thereof.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: May 1, 2007
    Assignee: Aventis Pharma Limited
    Inventors: Garry Fenton, Neil Victor Harris
  • Patent number: 7166616
    Abstract: The invention is directed to physiologically active compounds of general formula (I): wherein: represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a saturated 4 to 6 membered heterocyclic ring; R1 represents R3Z1-Het- or R4N(R5)—C(?O)—NH—Ar1—; L1 represents an —R6—R7— linkage; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; L2 represents an alkylene linkage; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (?4?1).
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: January 23, 2007
    Assignee: Aventis Pharma Limited
    Inventors: Neil Victor Harris, Garry Fenton
  • Publication number: 20040122047
    Abstract: The invention is directed to physiologically active compounds of formula (I): 1
    Type: Application
    Filed: November 18, 2003
    Publication date: June 24, 2004
    Applicant: Aventis Pharma Limited
    Inventors: Garry Fenton, Neil Victor Harris
  • Patent number: 6706738
    Abstract: The invention is directed to physiologically active compounds of general formula (I): R1Z1—Het—L1—Ar1—L2—Y  (I) wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring containing at least one heteroatom selected from O, S or N; R1 is optionally substituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; Z1 represents a direct bond, an alkylene chain, NR4, O or S(O)n; L1 is an a —R5—R6— linkage where R5 is alkylene, alkenylene or alkynylene and R6 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, —C(═Z3)—NR4—, —NR4—C(═Z3)—, —Z3—, —C(═O)—, —C(═NOR4)—, —NR4—, —NR4—C(═Z3)—NR4—, —SO2—NR4—, —NR4—SO2—, —O—C(═O)—, —C(═O)—O—,
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 16, 2004
    Assignee: Aventis Pharma Limited
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Publication number: 20040010022
    Abstract: The present invention relates to compounds of formula I: 1
    Type: Application
    Filed: February 12, 2003
    Publication date: January 15, 2004
    Inventors: Alexander William Oxford, Richard Anthony Borman, Robert Alexander Coleman, Kenneth Lyle Clark, George Hynd, Janet Ann Archer, Amanda Aley, Neil Victor Harris
  • Publication number: 20040006056
    Abstract: The invention is directed to physiologically active compounds of general formula (I): 1
    Type: Application
    Filed: May 1, 2003
    Publication date: January 8, 2004
    Inventors: Neil Victor Harris, Garry Fenton
  • Patent number: 6632814
    Abstract: The invention is directed to physiologically active compounds of formula (I): wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C2-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)—R9, —N(R8)—C(═O)—OR9, —N(R
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: October 14, 2003
    Assignees: Aventis Pharma Ltd., Aventis Pharmaceuticals Recherche Developpment
    Inventors: Jean-Dominique Bourzat, Alain Commercon, Bruno Jacques Christophe Filoche, Neil Victor Harris, Thomas David Pallin, Keith Alfred James Stuttle
  • Patent number: 6608084
    Abstract: The invention is directed to physiologically active compounds of formula (I) wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C1-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)R9, —N(R8)—SO2—R9, —NY4Y5 or —[C
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: August 19, 2003
    Assignees: Aventis Pharma Ltd., Aventis Recherche Developpment
    Inventors: Jean-Dominique Bourzat, Alain Commercon, Bruno Jacques Christophe Filoche, Neil Victor Harris, Clive McCarthy
  • Patent number: 6593354
    Abstract: The invention is directed to physiologically active compounds of formula (Ia): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is alkylene, alkenylene or alkynylene; R5 is hydrogen or lower alkyl; L2 is optionally substituted alkylene or alkenylene; Y is carboxy; and Z1 is NR5; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: July 15, 2003
    Assignee: Aventis Pharma Limited
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Patent number: 6562851
    Abstract: The invention is directed to physiologically active compounds of general formula (I): wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N; R1 is optionally substituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; Z1 is NR5; L1 is a —R6—R7— linkage (where R6 is alkylene, alkenylene or alkynylene and R7 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, —C(═Z3)—NR5—, —NR5—C(═Z3)—, —Z3—, —C(═O)—, —C(═NOR5)—, —NR5—, —NR5—C(═Z3)—NR5—, —SO2—NR5—, —NR5—SO2—, —O—C(═O)—, —C(═O)—O—, —NR5—C(═O)—O—
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: May 13, 2003
    Assignee: Aventis Pharma Limited
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Publication number: 20020173506
    Abstract: The invention is directed to physiologically active compounds of general formula (I):
    Type: Application
    Filed: October 11, 2001
    Publication date: November 21, 2002
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Patent number: 6479519
    Abstract: The invention is directed to physiologically active compounds of formula (I): wherein: R1 is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; X1, X2 and X6 independently represent N or CR10; and one of X3, X4 and X5 represents CR11 and the others independently represents N or CR10; where R10 is hydrogen, amino, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl; and R11 represents a group —L1—Ar1—L2—Y; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: November 12, 2002
    Assignee: Aventis Pharma Limited
    Inventors: Peter Charles Astles, David Edward Clark, Alan John Collis, Paul Joseph Cox, Paul Robert Eastwood, Neil Victor Harris, Justine Yeun Quai Lai, Andrew David Morley, Barry Porter
  • Publication number: 20020156111
    Abstract: The invention is directed to physiologically active compounds of general formula (I): 1
    Type: Application
    Filed: November 2, 2001
    Publication date: October 24, 2002
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Publication number: 20020137782
    Abstract: The invention is directed to physiologically active compounds of formula (Ia): 1
    Type: Application
    Filed: August 9, 2001
    Publication date: September 26, 2002
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive MCCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Patent number: 6352977
    Abstract: The invention is directed to physiologically active compounds of general formula (I): wherein R1 is hydrogen, halogen, lower alkyl or lower alkoxy; X1, X2 and X6 independently represent N or CR2; and one of X3, X4 and X5 represents CR3 and the others independently represents N or CR2 where R2 is hydrogen, halogen, lower alkyl or lower alkoxy; and R3 represents a group —L1—(CH2)n—C(═O)—N(R4)—CH2—CH2—Y; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: March 5, 2002
    Assignee: Aventis Pharma Limited
    Inventors: Peter Charles Astles, Neil Victor Harris, Andrew David Morley
  • Patent number: 6211234
    Abstract: Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: April 3, 2001
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Peter Charles Astles, Mark Francis Harper, Neil Victor Harris, Iain McFarlane McLay, Roger John Aitchison Walsh, Richard Alan Lewis, Christopher Smith, Barry Porter, Clive McCarthy
  • Patent number: 5630392
    Abstract: According to the present invention there is provided an exhaust brake of the sliding valve gate type comprising a piston cylinder device for operating the slidable valve gate to open or close the exhaust brake, an aperture through the valve gate for relieving manifold pressure, and control means for controlling the passage of exhaust gases through the aperture in the valve gate, wherein the control means is variably selectable to control venting of exhaust gases according to driving conditions of a vehicle as determined by the driver of the vehicle.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: May 20, 1997
    Assignee: Hersham Valves Limited
    Inventor: Victor A. Harris